Endra Life Sciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ENDRA Life Sciences reported a net loss of $7.03 million for 2025, faces substantial doubt about its ability to continue as a going concern, and is evaluating strategic alternatives while delaying its key FDA submission.
NASDAQ
ENDRA Life Sciences files an amendment to its annual report to correct a typographical error in the auditor's report regarding the date and PCAOB ID number.
NASDAQ
ENDRA Life Sciences Inc.'s 10-K filing reveals ongoing financial challenges and operating losses, despite advancements in its TAEUS technology and a strategic shift towards metabolic disease management.
NASDAQ
ENDRA Life Sciences Inc. released its 10-K filing, detailing its financial status, ongoing development of its TAEUS technology, and future strategic plans.